Skip to content

Aligos Therapeutics, Inc.

ALGS

CIK 0001799448

← back to feed
Revenue (TTM)
$4.85M
−39.5% YoY Q1 Mar 2026
Net Income (TTM)
−$27.35M
+81.6% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$8.89
+88.3% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
-1,920.8%
Q1 Mar 2026
Net Margin
-564.3%
Q1 Mar 2026
Free Cash Flow (TTM)
−$91.09M
Q1 Mar 2026
Cash
$29.98M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
42.61M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings